NO20042811L - Substituerte henzoksazoler og analoger som estrogene midler - Google Patents

Substituerte henzoksazoler og analoger som estrogene midler

Info

Publication number: NO20042811L
Authority: NO; Norway
Prior art keywords: henoxazoles; analogues; substituted; estrogenic agents; rog
Prior art date: 2001-12-05

Application number

NO20042811A

Other languages

English (en)

Norwegian (no)

Inventor

Michael David Collini

Heather Anne Harris

Jr James Carl Keith

Michael Sotirios Malamas

Robert Emmett Mcdevitt

Iwan Gunawan

Eric Steven Manas

Leo Massillamoney Albert

Cecil Richard Lyttle

Original Assignee

Wyeth Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-12-05

Filing date

2004-07-02

Publication date

2004-07-05

2004-07-02 Application filed by Wyeth Corp filed Critical Wyeth Corp

2004-07-05 Publication of NO20042811L publication Critical patent/NO20042811L/no

Links

239000000262 estrogen Substances 0.000 title 1
239000003814 drug Substances 0.000 abstract 1
229940079593 drug Drugs 0.000 abstract 1
239000002834 estrogen receptor modulator Substances 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D263/57—Aryl or substituted aryl radicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/18—Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
- C07D277/66—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2 with aromatic rings or ring systems directly attached in position 2
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Diabetes (AREA)
Endocrinology (AREA)
Urology & Nephrology (AREA)
Cardiology (AREA)
Reproductive Health (AREA)
Biomedical Technology (AREA)
Heart & Thoracic Surgery (AREA)
Immunology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Dermatology (AREA)
Hematology (AREA)
Obesity (AREA)
Rheumatology (AREA)
Pulmonology (AREA)
Vascular Medicine (AREA)
Pregnancy & Childbirth (AREA)
Gynecology & Obstetrics (AREA)
Hospice & Palliative Care (AREA)
Orthopedic Medicine & Surgery (AREA)
Pain & Pain Management (AREA)
Communicable Diseases (AREA)
Emergency Medicine (AREA)
Transplantation (AREA)
Biochemistry (AREA)

NO20042811A 2001-12-05 2004-07-02 Substituerte henzoksazoler og analoger som estrogene midler NO20042811L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US33666301P	2001-12-05	2001-12-05
PCT/US2002/038513 WO2003050095A1 (en)	2001-12-05	2002-12-03	Substituted benzoxazoles and analogues as estrogenic agents

Publications (1)

Publication Number	Publication Date
NO20042811L true NO20042811L (no)	2004-07-05

Family

ID=23317104

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20042811A NO20042811L (no)	2001-12-05	2004-07-02	Substituerte henzoksazoler og analoger som estrogene midler

Country Status (24)

Country	Link
US (4)	US6794403B2 (es)
EP (2)	EP1982713A3 (es)
JP (2)	JP4689960B2 (es)
KR (1)	KR20050044717A (es)
CN (2)	CN100443477C (es)
AR (1)	AR037745A1 (es)
AU (2)	AU2002353014A1 (es)
BR (1)	BR0214767A (es)
CA (1)	CA2467517C (es)
CO (1)	CO5580830A2 (es)
EC (1)	ECSP045133A (es)
HU (1)	HUP0500010A2 (es)
IL (1)	IL162256A0 (es)
IN (1)	IN2005KO00272A (es)
MX (1)	MXPA04005306A (es)
NO (1)	NO20042811L (es)
NZ (1)	NZ560878A (es)
PL (1)	PL370771A1 (es)
RU (2)	RU2330847C2 (es)
SG (1)	SG165987A1 (es)
TW (1)	TW200304822A (es)
UA (1)	UA83620C2 (es)
WO (1)	WO2003050095A1 (es)
ZA (1)	ZA200405249B (es)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2286322T3 (es)	2001-11-19	2007-12-01	Eli Lilly And Company	Benzopirianos como agosnistas selectivos de receptores de estrogenos beta.
UA83620C2 (ru)	2001-12-05	2008-08-11	Уайт	Замещенные бензоксазолы и их аналоги как эстрогенные агенты
US20040002524A1 (en) *	2002-06-24	2004-01-01	Richard Chesworth	Benzimidazole compounds and their use as estrogen agonists/antagonists
TW200409759A (en) *	2002-09-25	2004-06-16	Wyeth Corp	Substituted 4-(indazol-3-yl)phenols
CN101413143B (zh)	2002-12-19	2013-09-18	斯克里普斯研究学院	稳定甲状腺素运载蛋白和抑制甲状腺素运载蛋白错折叠的组合物和方法
SI1626974T1 (sl) *	2003-04-21	2009-02-28	Lilly Co Eli	Substituirani benzopirani kot selektivni agonistiestrogenskega receptorja beta
TW200500065A (en) *	2003-05-21	2005-01-01	Wyeth Corp	Antiarthritic combinations
AU2005245470A1 (en) *	2004-05-20	2005-12-01	Foldrx Pharmaceuticals, Inc.	2-((hetero) aryl)-benzoxazole compounds and derivatives, compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding
WO2006007503A1 (en) *	2004-07-01	2006-01-19	Wyeth	Tetracyclic compounds as estrogen ligands
TW200612925A (en) *	2004-08-26	2006-05-01	Wyeth Corp	Prodrug substituted benzoxazoles as estrogenic agents
WO2006028875A1 (en)	2004-09-02	2006-03-16	Wyeth	Phenanthridine carbonyl phenols as cytokine modulators
CA2578164A1 (en)	2004-09-07	2006-03-16	Wyeth	6h-[1]benzopyrano[4,3-b]quinolines and their use as estrogenic agents
EP1819322A2 (en) *	2004-12-02	2007-08-22	Wyeth a Corporation of the State of Delaware	Formulations of substituted benzoxazoles
SV2006002317A (es) *	2004-12-02	2006-06-26	Wyeth Corp	Formulaciones de benzoxazoles substituidos ref. wyth0097-503 (am101641) (178701)
BRPI0518789A2 (pt) *	2004-12-02	2008-12-09	Wyeth Corp	formulaÇço farmacÊutica, processo para preparar uma formulaÇço farmacÊutica, produto, e, cÁpsula ou tablete
KR20070086329A (ko) *	2004-12-17	2007-08-27	와이어쓰	에스트로겐 베타 아고니스트의 신규 용도
US8093302B2 (en) *	2005-02-15	2012-01-10	Eli Lilly And Company	Substituted tetralins as selective estrogen receptor-β agonists
BRPI0608154A2 (pt) *	2005-02-16	2016-10-11	Wyeth Corp	métodos de tratar ou inibir mucosite, cistite por radiação em um indivíduo, e de tratar pelo menos um sintoma de exposição de um indivíduo a um agente citotóxico ou à radiação, e, composição farmacêutica
SG160353A1 (en) *	2005-03-07	2010-04-29	Wyeth Corp	Process for the preparation of substituted benzoxazole compounds
US7579478B2 (en)	2005-03-07	2009-08-25	Wyeth	Process for the purification of substituted benzoxazole compounds
CA2600339A1 (en) *	2005-03-08	2006-09-14	Wyeth	Crystal forms of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol and their use as estrogen receptor modulators
US7973025B2 (en)	2005-05-26	2011-07-05	Neuron Systems, Inc.	Compositions and methods of treating retinal disease
PE20070427A1 (es)	2005-08-30	2007-04-21	Novartis Ag	Compuestos derivados de benzimidazoles sustituidos como inhibidores de tirosina quinasas
AR059574A1 (es) *	2006-02-14	2008-04-16	Wyeth Corp	Formulaciones farmaceuticas acuosas de ligandos selectivos er-beta
WO2007103869A2 (en) *	2006-03-06	2007-09-13	Wyeth	Liquid and semi-solid pharmaceutical formulations and processes
MX2008011459A (es) *	2006-03-06	2008-09-24	Wyeth Corp	Formulaciones y procesos para tabletas.
AR059743A1 (es) *	2006-03-06	2008-04-23	Wyeth Corp	Formulaciones farmaceuticas de una forma cristalina de monohidrato de 2- (3- fluor-4- hidroxifenil )-7- vinil-1,3- benzoaxol-5-ol
US20070208069A1 (en) *	2006-03-06	2007-09-06	Wyeth	Pharmaceutical formulations of an anhydrous crystal form of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol
JP4986485B2 (ja)	2006-03-28	2012-07-25	株式会社Ａｄｅｋａ	エポキシ樹脂硬化性組成物
EP2074223A4 (en) *	2006-09-15	2010-03-10	Foldrx Pharmaceuticals Inc	TEST PROCEDURE FOR THE DETECTION OF PROTEINS IN THE NATIVE CONDITION AND FOR THE IDENTIFICATION OF THE STABILITY OF PROTEINS IN THE NATIVE CONDITION MODULATING COMPOUNDS
US20080176914A1 (en) *	2006-11-21	2008-07-24	Wyeth	Crystal form of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol
WO2008064217A2 (en) *	2006-11-21	2008-05-29	Wyeth	Crystal forms of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol and pharmaceutical formulations thereof
US20080241234A1 (en) *	2006-11-21	2008-10-02	Wyeth	Pharmaceutical formulations of an anhydrate crystal form of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol
US20080175901A1 (en) *	2006-11-21	2008-07-24	Wyeth	Pharmaceutical formulations of a crystal form of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol
US20080139633A1 (en) *	2006-11-21	2008-06-12	Wyeth	Crystal form of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol
US20090239920A1 (en) *	2006-11-21	2009-09-24	Wyeth	Pharmaceutical formulations of an anhydrate crystal form of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol
US20080132554A1 (en) *	2006-11-21	2008-06-05	Wyeth	Crystal form of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol
US20080146630A1 (en) *	2006-11-21	2008-06-19	Wyeth	Crystal form of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol
US20080175900A1 (en) *	2006-11-21	2008-07-24	Wyeth	Pharmaceutical formulations of an anhydrate crystal form of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol
EP2106212B1 (en)	2007-01-22	2014-04-02	GTX, Inc.	Nuclear receptor binding agents
US9604931B2 (en)	2007-01-22	2017-03-28	Gtx, Inc.	Nuclear receptor binding agents
US9623021B2 (en) *	2007-01-22	2017-04-18	Gtx, Inc.	Nuclear receptor binding agents
TW200838509A (en) *	2007-01-31	2008-10-01	Wyeth Corp	Use of ERβ selective ligands for treating acute lung injuries
US20080194533A1 (en) *	2007-02-09	2008-08-14	Wyeth	Process for selective sulfation of aromatic hydroxyl groups
US20080262009A1 (en) *	2007-04-20	2008-10-23	Wyeth	Crystalline polymorphs of n-(3-(dimethylamino)propyl)-4-(4-(3-fluoro-4-methoxyphenyl) pyrimidin-2-ylamino) benzenesulfonamide as acetate salts
US20080275073A1 (en) *	2007-04-20	2008-11-06	Wyeth	Crystalline forms and polymorphs of n-(3-(dimethylamino)propyl)-4-(4-(3-fluoro-4-methoxyphenyl) pyrimidin-2-ylamino) benzenesulfonamide as pharmaceutically acceptable salts
US20080262008A1 (en) *	2007-04-20	2008-10-23	Wyeth	Crystalline forms and polymorphs of n-(3-(dimethylamino)propyl)-4-(4-(3-fluoro-4-methoxyphenyl) pyrimidin-2-ylamino) benzenesulfonamide as succinate salts
US20080262010A1 (en) *	2007-04-20	2008-10-23	Wyeth	Crystalline polymorphs of n-(3-(dimethylamino)propyl)-4-(4-(3-fluoro-4-methoxyphenyl) pyrimidin-2-ylamino) benzenesulfonamide as d-glucoronate salts
US20090010884A1 (en) *	2007-07-06	2009-01-08	Wyeth	Pharmaceutical compositions and methods of preventing, treating, or inhibiting inflammatory diseases, disorders, or conditions of the skin, and diseases, disorders, or conditions associated with collagen depletion
JP2011511803A (ja) *	2008-02-08	2011-04-14	ワイス・エルエルシー	置換ベンゾオキサゾールのホスファート誘導体
EP2350032B1 (en) *	2008-09-26	2016-05-25	Eisai R&D Management Co., Ltd.	Benzoxazole compounds and methods of use
WO2010036908A1 (en) *	2008-09-26	2010-04-01	Eisai R & D Management Co., Ltd.	Use of benzoxazole compounds in the treatment of malaria
WO2010083199A1 (en)	2009-01-19	2010-07-22	Abbott Laboratories	Benzthiazole inhibitors of poly(adp-ribose)polymerase
WO2011014516A1 (en) *	2009-07-28	2011-02-03	University Of Pittsburgh - Of The Commonwealth System Of Higher Education	Estrogen antagonists as treatments for sclerosing disorders
WO2011072141A1 (en)	2009-12-11	2011-06-16	Neuron Systems, Inc.	Compositions and methods for the treatment of macular degeneration
US20130191934A1 (en) *	2010-10-01	2013-07-25	Indiana University Research And Technology Corpora	Treatment of symptoms associated with menopause
US8865754B2 (en) *	2011-03-03	2014-10-21	Proteotech Inc.	Compounds for the treatment of neurodegenerative diseases
WO2013038351A1 (en)	2011-09-16	2013-03-21	Pfizer Inc.	Solid forms of a transthyretin dissociation inhibitor
BR112015015218B1 (pt) *	2012-12-27	2020-12-01	Sumitomo Chemical Company, Limited	composto de oxazol fusionado, agente e método para controlar pragas
SG11201505587YA (en)	2013-01-23	2015-08-28	Aldeyra Therapeutics Inc	Toxic aldehyde related diseases and treatment
CA2898869A1 (en)	2013-01-25	2014-07-31	Aldeyra Therapeutics, Inc.	Novel traps in the treatment of macular degeneration
JPWO2016021706A1 (ja) *	2014-08-08	2017-05-25	カズマパートナーズ株式会社	縮合複素環化合物
WO2016036721A1 (en)	2014-09-02	2016-03-10	The Regents Of The University Of California	Estrogen receptor ligand treatment for neurodegenerative diseases
CN104926745A (zh) *	2015-07-14	2015-09-23	佛山市赛维斯医药科技有限公司	含苯并异恶唑和末端卤代苄基类结构的化合物及其用途
CN104974103A (zh) *	2015-07-14	2015-10-14	佛山市赛维斯医药科技有限公司	一类含苯并异恶唑和烷氧苯基类结构的化合物及其用途
AU2016311158A1 (en)	2015-08-21	2018-04-05	Aldeyra Therapeutics, Inc.	Deuterated compounds and uses thereof
WO2017196881A1 (en)	2016-05-09	2017-11-16	Aldeyra Therapeutics, Inc.	Combination treatment of ocular inflammatory disorders and diseases
CA3054811A1 (en)	2017-03-16	2018-09-20	Aldeyra Therapeutics, Inc.	Polymorphic compounds and uses thereof
MX2020003425A (es)	2017-10-10	2020-07-29	Aldeyra Therapeutics Inc	Tratamiento de trastornos inflamatorios.
CN108586374B (zh) *	2018-01-12	2021-01-05	浙江鼎龙科技有限公司	2-苯基苯并噁唑类化合物的制备方法
EP3833660A4 (en)	2018-08-06	2022-05-11	Aldeyra Therapeutics, Inc.	POLYMORPHIC COMPOUNDS AND THEIR USES
JP2022530967A (ja)	2019-05-02	2022-07-05	アルデイラセラピューティクス，インコーポレイテッド	多形化合物およびその使用
US12098132B2 (en)	2019-05-02	2024-09-24	Aldeyra Therapeutics, Inc.	Process for preparation of aldehyde scavenger and intermediates
CN111467341B (zh) *	2020-04-24	2021-05-11	山东师范大学	3,4-二甲氧基苯基-苯并[d]恶唑作为肿瘤耐药逆转剂的应用
CA3175856A1 (en)	2020-05-13	2021-11-18	Todd Brady	Pharmaceutical formulations and uses thereof
CN114805112A (zh) *	2022-05-31	2022-07-29	常州大学	一种pde2抑制剂酰胺类衍生物及其制备方法

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1435721A (en) *	1972-05-18	1976-05-12	Lilly Industries Ltd	Benzoxazole derivatives
GB1590587A (en)	1977-06-28	1981-06-03	Lilly Industries Ltd	Benoxaprofen
CZ104795A3 (en) *	1994-04-29	1996-02-14	Lilly Co Eli	Benzimidazole derivative, process of its preparation, its use for preparing a pharmaceutical preparation and the pharmaceutical composition containing thereof
DK0792292T4 (da)	1995-09-08	2009-07-20	Karobio Ab	Orphan-receptor
AU4988997A (en)	1996-10-23	1998-05-15	Osteoscreen, Inc.	Compositions and methods for treating bone deficit conditions
US5948776A (en) *	1996-10-23	1999-09-07	Zymogenetic, Inc.	Compositions and methods for treating bone deficit conditions
US5919808A (en) *	1996-10-23	1999-07-06	Zymogenetics, Inc.	Compositions and methods for treating bone deficit conditions
US7157568B1 (en)	1997-08-05	2007-01-02	American Home Products Corporation	Human estrogen receptor-β
IL139317A0 (en)	1998-05-05	2001-11-25	Byk Gulden Lomberg Chem Fab	Benzimdazole and benzoxazole derivatives and pharmaceutical compositions contining the same
GB9814620D0 (en)	1998-07-06	1998-09-02	Karobio Ab	Vasculoprotector
IL140468A0 (en)	1998-07-06	2002-02-10	Byk Gulden Lomberg Chem Fab	Benzoxazole derivatives and pharmaceutical compositions containing the same
WO2000019994A1 (en)	1998-10-02	2000-04-13	Board Of Trustees Of The University Of Illinois	Estrogen receptor ligands
AU1967300A (en)	1998-11-20	2000-06-13	Akzo Nobel N.V.	Estrogenic estra-1,3,5(10)-trienes with differential effects on the alpha and beta estrogen receptors, having a linear hydrocarbon chain of from 5-9 carbon atoms in position 11
CA2356986A1 (en)	1998-12-30	2000-07-06	Signal Pharmaceuticals, Inc.	Compounds and methods for modulation of estrogen receptors
US6331562B1 (en) *	1998-12-30	2001-12-18	Signal Pharmaceuticals, Inc.	Compounds and methods for modulation of estrogen receptors
US6358943B1 (en) *	1999-03-04	2002-03-19	American Home Products Corporation	N-substituted indolines as estrogenic agents
WO2000055137A1 (en) *	1999-03-17	2000-09-21	Signal Pharmaceuticals, Inc.	Compounds and methods for modulation of estrogen receptors
WO2000059897A2 (en)	1999-04-06	2000-10-12	Akzo Nobel N.V.	Esters and carbonates of 2-(4-hydroxyphenyl)-6(or 5)-hydroxy-benzothiophene derivatives as selective estrogenic compounds
WO2000061230A2 (en)	1999-04-09	2000-10-19	Karo Bio Ab	Estrogen receptors-beta antagonism and bone diseases
EP1173164A2 (en)	1999-04-16	2002-01-23	AstraZeneca AB	Estrogen receptor-beta ligands
US6159959A (en) *	1999-05-06	2000-12-12	American Home Products Corporation	Combined estrogen and antiestrogen therapy
GB9913649D0 (en)	1999-06-11	1999-08-11	Karobio Ab	Estrogen receptor
US6380166B1 (en) *	1999-09-13	2002-04-30	American Home Products Corporation	Glucopyranosides conjugates of 2-(4-hydroxy-phenyl)-3-methyl-1-[4-(2-amin-1-yl-ethoxy)-benzyl]-1H-indol-5-ols
WO2001082923A1 (en)	2000-02-14	2001-11-08	Merck & Co., Inc.	Estrogen receptor modulators
AU2002221239A1 (en) *	2000-12-07	2002-06-18	Astrazeneca Ab	Therapeutic benzimidazole compounds
JP2004524289A (ja) *	2000-12-22	2004-08-12	アストラゼネカ・アクチエボラーグ	治療化合物
US6559177B2 (en) *	2001-04-19	2003-05-06	Wyeth	5, 11-Dioxa-benzo[b]fluoren-10-one and 5-oxa-11-thia-benzo[b]fluoren-10-ones as estrogenic agents
UA83620C2 (ru) *	2001-12-05	2008-08-11	Уайт	Замещенные бензоксазолы и их аналоги как эстрогенные агенты
TW200612925A (en) *	2004-08-26	2006-05-01	Wyeth Corp	Prodrug substituted benzoxazoles as estrogenic agents

2002
- 2002-03-12 UA UA20040705301A patent/UA83620C2/ru unknown
- 2002-12-03 NZ NZ560878A patent/NZ560878A/en unknown
- 2002-12-03 CN CNB028278186A patent/CN100443477C/zh not_active Expired - Fee Related
- 2002-12-03 JP JP2003551120A patent/JP4689960B2/ja not_active Expired - Fee Related
- 2002-12-03 CN CNA2008101731403A patent/CN101423500A/zh active Pending
- 2002-12-03 HU HU0500010A patent/HUP0500010A2/hu unknown
- 2002-12-03 AU AU2002353014A patent/AU2002353014A1/en not_active Abandoned
- 2002-12-03 IL IL16225602A patent/IL162256A0/xx unknown
- 2002-12-03 EP EP07023848A patent/EP1982713A3/en not_active Withdrawn
- 2002-12-03 BR BR0214767-0A patent/BR0214767A/pt not_active IP Right Cessation
- 2002-12-03 RU RU2004120283/04A patent/RU2330847C2/ru active
- 2002-12-03 CA CA2467517A patent/CA2467517C/en not_active Expired - Fee Related
- 2002-12-03 PL PL02370771A patent/PL370771A1/xx unknown
- 2002-12-03 KR KR1020047008680A patent/KR20050044717A/ko not_active Abandoned
- 2002-12-03 MX MXPA04005306A patent/MXPA04005306A/es active IP Right Grant
- 2002-12-03 WO PCT/US2002/038513 patent/WO2003050095A1/en not_active Ceased
- 2002-12-03 SG SG200603829-3A patent/SG165987A1/en unknown
- 2002-12-03 EP EP02789980A patent/EP1451165A1/en not_active Withdrawn
- 2002-12-03 TW TW091135030A patent/TW200304822A/zh unknown
- 2002-12-04 AR ARP020104690A patent/AR037745A1/es unknown
- 2002-12-04 US US10/309,699 patent/US6794403B2/en not_active Expired - Fee Related
2004
- 2004-05-17 US US10/847,100 patent/US7148247B2/en not_active Expired - Fee Related
- 2004-06-01 CO CO04050963A patent/CO5580830A2/es not_active Application Discontinuation
- 2004-06-04 EC EC2004005133A patent/ECSP045133A/es unknown
- 2004-07-01 ZA ZA200405249A patent/ZA200405249B/en unknown
- 2004-07-02 NO NO20042811A patent/NO20042811L/no not_active Application Discontinuation
- 2004-08-19 US US10/921,409 patent/US7129258B2/en not_active Expired - Fee Related
2005
- 2005-04-04 IN IN272KO2005 patent/IN2005KO00272A/en unknown
2006
- 2006-12-11 US US11/636,947 patent/US7531564B2/en not_active Expired - Fee Related
2008
- 2008-02-26 RU RU2008107295/04A patent/RU2008107295A/ru not_active Application Discontinuation
2009
- 2009-08-17 AU AU2009210357A patent/AU2009210357A1/en not_active Ceased
2010
- 2010-11-15 JP JP2010255175A patent/JP2011052010A/ja active Pending

Also Published As

Publication number	Publication date
RU2008107295A (ru)	2009-09-10
CA2467517A1 (en)	2003-06-19
WO2003050095A1 (en)	2003-06-19
IL162256A0 (en)	2005-11-20
JP2005520794A (ja)	2005-07-14
CN100443477C (zh)	2008-12-17
AU2009210357A1 (en)	2009-09-10
US20070167503A1 (en)	2007-07-19
EP1982713A2 (en)	2008-10-22
ZA200405249B (en)	2007-01-31
SG165987A1 (en)	2010-11-29
NZ560878A (en)	2009-03-31
PL370771A1 (en)	2005-05-30
US20030199562A1 (en)	2003-10-23
MXPA04005306A (es)	2004-09-13
US20050080117A1 (en)	2005-04-14
EP1451165A1 (en)	2004-09-01
CA2467517C (en)	2011-05-03
TW200304822A (en)	2003-10-16
IN2005KO00272A (es)	2015-08-07
US7531564B2 (en)	2009-05-12
CN1646504A (zh)	2005-07-27
UA83620C2 (ru)	2008-08-11
BR0214767A (pt)	2004-11-09
RU2330847C2 (ru)	2008-08-10
US7148247B2 (en)	2006-12-12
US20050239851A1 (en)	2005-10-27
CO5580830A2 (es)	2005-11-30
US7129258B2 (en)	2006-10-31
AU2002353014A1 (en)	2003-06-23
AR037745A1 (es)	2004-12-01
EP1982713A3 (en)	2009-03-25
ECSP045133A (es)	2004-07-23
CN101423500A (zh)	2009-05-06
RU2004120283A (ru)	2005-03-27
JP2011052010A (ja)	2011-03-17
JP4689960B2 (ja)	2011-06-01
HUP0500010A2 (hu)	2005-04-28
US6794403B2 (en)	2004-09-21
KR20050044717A (ko)	2005-05-12

Legal Events

Date	Code	Title	Description
2010-01-25	FC2A	Withdrawal, rejection or dismissal of laid open patent application

Publication	Publication Date	Title
NO20042811L (no)	2004-07-05	Substituerte henzoksazoler og analoger som estrogene midler
DK1653947T3 (da)	2008-04-28	(Hydroxyphenyl)-1H-indol-3-carbaldehydoximderivater som östrogenmidler
DK1620392T3 (da)	2007-10-15	Hydroxy-biphenyl-carbaldehydoxim-derivater og deres anvendelse som östrogene midler
NO20021328L (no)	2002-05-21	Pyrazolopyrimidier som terapeutiske midler
DK1506185T3 (da)	2006-10-02	Forbindelser og deres anvendelse som 5-HT-inhibitorer
MXPA04004674A (es)	2004-08-12	Ligados de los receptors de los canabinodies.
MXPA05009985A (es)	2005-11-04	Ligandos de receptores de canabinoides.
DK1633699T3 (da)	2007-03-26	Aryl-carbaldehydroximderivater og deres anvendelse som östrogene midler
BR0215042A (pt)	2006-06-06	fenil-naftalenos substituìdos como agentes estrogênicos
SE0302760D0 (sv)	2003-10-20	New compounds
NO20055135L (no)	2005-12-14	Fenylguinoliner og deres anvendelse som ostrogenreseptormodulatorer
DK1392714T3 (da)	2006-01-09	Steroider som agonister for FXR
NO20033732L (no)	2003-10-22	N-substituerte ikke-aryl-heterosykliske NMDA/NR2B-antagonister, og farmasoytiske preparater som omfatter slike forbindelser.
NO20081844L (no)	2008-05-29	Terapeutiske forbindelser
NO20054868L (no)	2005-12-20	CaSr antagonist
NO20071159L (no)	2007-03-26	Prodmedikamentsubstituerte benzoksazoler som ostrogene midler
MXPA04005784A (es)	2004-09-13	2-fenilbenzofuranos sustituidos como agentes estrogenitos.
NO20040881L (no)	2004-04-19	Orale antidiabetes midler.
NO20054848L (no)	2005-10-20	Substituerte p-diaminobenzenderivater
PA8568101A1 (es)	2003-11-12	Indolil-urea derivados de tienopiridinas utiles como agentes antiangiogenicos, y procedimientos para su uso
NO20001781L (no)	2000-10-09	3-amino-3-arylpropan-1-og lignende-derivater, deres fremstilling og anvendelse
AP1766A (en)	2007-08-10	Novel crystalline polymorphic forms of lercanidipine hydrochloride and process for their preparation.
NO20001514L (no)	2000-03-23	Vitronectin-reseptor-antagonist
BR0314844A (pt)	2005-08-09	Novo composto
BR0314843A (pt)	2005-08-09	Novo composto